Aims To assess cytokine levels in peripheral blood and tears of patients after allogeneic haematopoietic stem cell ...

Ryoncil ® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company’s Biologic ...

The authors found comparable results among patients in all 3 donor categories. For instance, the 2-year overall survival (OS) ...

MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T ...

Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory ...

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast Limited announced that its allogeneic cell therapy products, manufactured ...

Picture this: you’re surviving cancer, chemotherapy, radiation, immunosuppression, and a blood stem cell transplant, and you haven’t left the hospital in weeks. Yet, somehow, you have what feels and ...

CancerBuddy connects users through shared diagnoses and experiences, offering community when hospital walls feel especially ...

On September 23, 2025, MiNK Therapeutics elected Dr. John Holcomb as a Class II director, with his term expiring in 2026. Dr. Holcomb, a renowned expert in trauma and critical care, joins MiNK to ...

The first national, multi-center study to evaluate the full donor search process using a score-based strategy, 1 researchers tested whether the approach could help transplant centers avoid lengthy, ...

Thanks to in-utero blood transfusion technology, what was once a fatal diagnosis in the womb can now result in live births. However, this medical advancement created a new challenge: a growing ...